GHRP-6
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic six-amino-acid peptide that spikes growth hormone via the ghrelin receptor, marketed for muscle gain, recovery, and appetite. Higher GH and IGF-1 are its dependable effects, while claims of heart and organ protection rest only on animal and mechanism data. It drives the strongest hunger of any GHRP, can raise cortisol and blood sugar, with no long-term human safety data. Not FDA-approved; unregulated products sold online vary in purity.
Read Full recordStudied uses & evidence
Studied uses(7)
Potent GH release
HighHuman crossover trials confirm strong GH release, exceeding GHRH alone and synergistic when combined.
Cardioprotection
LowAnimal studies in rats, pigs, and dogs show protection against heart damage; no human trials yet.
Cytoprotection (multi-organ)
LowRat ischemia-reperfusion models show liver, kidney, lung, and gut protection; no human data.
Evidence limits
- Evidence Level
- Mostly Preclinical
Extensive preclinical evidence for GH secretion, cardioprotection, and cytoprotection across multiple organ systems. Human studies limited to GH-stimulation tests (healthy volunteers and children with short stature), diagnostic use for pituitary reserve evaluation, and comparative studies in Cushing's disease. Oral GHRP-6 (300 mcg/kg) shown effective in children. A Phase III trial of GHRP-6 combined with EGF in 188 stroke patients missed its primary endpoint. This does not establish efficacy of GHRP-6 alone; cardiac and multi-organ protection remain preclinical.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighGH secretagogue — promotes tumor growth via GH/IGF-1.
Eating disorders
HighGHRP-6 causes intense hunger through ghrelin activation. Problematic for binge eating.
Diabetic retinopathy
HighGH/IGF-1 elevation can worsen retinal neovascularization.
Diabetes/insulin resistance
ModerateGH elevation can worsen blood sugar control and insulin sensitivity.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Intense appetite stimulation (strongest among GHRPs)
HighCortisol and ACTH elevation (non-selective GHS-R activation)
ModerateProlactin elevation; potential gynecomastia with chronic use
LowWater retention and joint discomfort from GH/IGF-1
LowBlood glucose effects; potential insulin resistance
ModerateNo long-term human safety data
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.